You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 37 No. 9, September 1980 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Serum Haloperidol Determinations in Psychiatric Patients

Comparison of Methods and Correlation With Serum Prolactin Level

Robert T. Rubin, MD, PhD; Anders Forsman, MD; Jos Heykants, PhD; Rolf ühman, MD, PhD; Marcel Michiels

Arch Gen Psychiatry. 1980;37(9):1069-1074.


Abstract

• Twenty-one serum samples from 11 schizophrenic patients receiving long-term haloperidol therapy were analyzed for haloperidol concentrations by two different radioimmunoassays (RIAs) and gas chromatography (GC). There was a good correspondence between the RIA and GC values over a wide range of drug concentrations. However, compared with the specific GC technique, both RIA methods overestimated haloperidol concentrations, reflecting differences in the specificities of the two RIA antibodies. One of the RIA methods had the requisite specificity for application to patients treated with long-term haloperidol therapy, although further methodological refinement will be required for its general clinical application. Haloperidol values determined by GC and RIA analyses correlated highly with prolactin concentrations in the same samples, suggesting that the usefulness of prolactin measurement as an "in vivo bioassay" for circulating levels of haloperidol should be further explored.



Author Affiliations

Barbara Tower

From the Department of Psychiatry, Harbor/UCLA Medical Center, Torrance, Calif (Dr Rubin and Ms Tower); the Department of Psychiatry III, Lillhagen's Hospital, University of Güteborg, Sweden (Drs Forsman and Ühman); and the Department of Drug Metabolism, Janssen Pharmaceutica, Beerse, Belgium (Dr Heykants and Mr Michiels).


Footnotes

Accepted for publication June 29, 1979.

Reprint requests to B-4 Neuroendocrine Laboratory, Harbor/UCLA Medical Center, Torrance, CA 90509 (Dr Rubin).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1980 American Medical Association. All Rights Reserved.